Ebola Virus Clinical Trial
Official title:
A Phase 1 Randomized, Single-Center, Double-Blind, Placebo Controlled, Dose-Escalation Study to Evaluate the Safety and Immunogenicity of the BPSC-1001 (VSVΔG-ZEBOV) Ebola Virus Vaccine Candidate in Healthy Adult Subjects
This is a study of the anti-Ebola vaccine vesicular stomatitis virus (VSV) ZEBOV (Zaire ebolavirus) also known as V920 and BPSC-1001. The purpose of this study is to test how safe the vaccine is in humans and how well it makes the human immune system cause an immune- or defense-response to Ebola virus. This vaccine will be studied at different doses.
This study is being conducted to assess whether this vaccine is safe, and if it causes the
body to create an infection-fighting response. Between 1994 and the present, there have been
many Ebola virus outbreaks caused by 4 different strains of the virus, affecting mostly
people living in central Africa and the health care providers trying to treat them. Ebola
viruses are members of the filoviridae virus family, which also includes the dangerous
Marburg virus. Ebola virus causes severe and often deadly infection called a viral
hemorrhagic fever, characterized by organ failure, bleeding, and death.
To date, the virus is found primarily in Central and West Africa. It is not clear where these
viruses come from, but it is thought that bats are the most likely source of the human
outbreaks that occur. Once an outbreak occurs, the virus is spread from person to person
through direct contact with infected blood or body fluids with an infected individual.
Given the recent increase in Ebola virus infections occurring in Africa, there is interest in
making an effective vaccine to protect against the infection. V920/BPSC-1001 is an
experimental Ebola vaccine candidate demonstrating protection against Ebola virus in animal
experiments.
This is a Phase 1 study to evaluate a novel vaccine to Ebola using a live VSV replacing the
gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein
from the Zaire strain of Ebola (VSVΔG-ZEBOV also known as V920 and BPSC-1001). This phase 1
protocol provides a first-in-human study to evaluate the safety and toxicity of
V920/BPSC-1001 in healthy adult participants. Participants will be randomized to receive
V920/BPSC-1001 or Placebo by intramuscular injection. Three dose levels will be assessed with
follow-up visits through 180 days after the injection.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02271347 -
An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease
|
Phase 2 | |
| Completed |
NCT03719586 -
Investigational Therapeutics for the Treatment of People With Ebola Virus Disease
|
Phase 2/Phase 3 | |
| Completed |
NCT04041570 -
Ebola Sudan Chimpanzee Adenovirus Vector Vaccine in Healthy Adults
|
Phase 1 | |
| Completed |
NCT02344407 -
Partnership for Research on Ebola Vaccines in Liberia (PREVAIL)
|
Phase 2 | |
| Completed |
NCT02314923 -
Placebo Controlled, Dose Response, Safety and Immunogenicity Study of Vesicular Stomatitis Virus (VSV) Ebola Vaccine in Healthy Adults (V920-004)
|
Phase 1 |